Bagatelle Cassidy Syndrome: Macrocephaly
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pfeiffer Syndrome Type II Discovered Perinatally
Diagnostic and Interventional Imaging (2012) 93, 785—789 CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector LETTER / Musculoskeletal imaging Pfeiffer syndrome type II discovered perinatally: Report of an observation and review of the literature a,∗ a a a H. Ben Hamouda , Y. Tlili , S. Ghanmi , H. Soua , b c b a S. Jerbi , M.M. Souissi , H. Hamza , M.T. Sfar a Unité de néonatologie, service de pédiatrie, CHU Tahar Sfar, 5111 Mahdia, Tunisia b Service de radiologie, CHU Tahar Sfar, 5111 Mahdia, Tunisia c Service de gynéco-obstétrique, CHU Tahar Sfar, 5111 Mahdia, Tunisia Pfeiffer syndrome, described for the first time by Pfeiffer in 1964, is a rare hereditary KEYWORDS condition combining osteochondrodysplasia with craniosynostosis [1]. This syndrome is Pfeiffer syndrome; also called acrocephalosyndactyly type 5, which is divided into three sub-types. Type I Cloverleaf skull; is the classic Pfeiffer syndrome, with autosomal dominant transmission, often associated Craniosynostosis; with normal intelligence. Types II and III occur as sporadic cases in individuals who have Syndactyly; craniosynostosis with broad thumbs, broad big toes, ankylosis of the elbows and visceral Prenatal diagnosis abnormalities [2]. We report a case of Pfeiffer syndrome type II, discovered perinatally, which is distinguished from type III by the skull appearing like a cloverleaf, and we shall discuss the clinical, radiological and evolutive features and the advantage of prenatal diagnosis of this syndrome with a review of the literature. Observation The case involved a male premature baby born at 36 weeks of amenorrhoea with multiple deformities at birth. The parents were not blood-related and in good health who had two other boys and a girl with normal morphology. -
Megalencephaly and Macrocephaly
277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ► -
Crouzon Syndrome with Ophthalmological Complications
Journal of Rawalpindi Medical College (JRMC); 2012;16(1):80-81 Case Report Crouzon Syndrome With Ophthalmological Complications Rahela Nasir Paediatric Department, Capital Hospital, CDA Islamabad. Crouzon Syndrome is characterized by premature bilateral optic atrophy. Other facial features included a craniosynostosis. It has an autosomal dominant inheritance prominent nose and deep and narrow palate. No but represents fresh mutation also. Other craniofacial digital abnormalities were seen. No dental aplasia was abnormalities include ocular proptosis caused by shallow present. Systemic examination revealed no orbits with or without divergent strabismus. There may be abnormality. increased intracranial pressure for which surgical morcellation procedures are indicated. A case of He was diagnosed as a case of Crouzon syndrome craniosynostosis is reported which is diagnosed as Crouzon with ocular complications on clinical basis. He was Syndrome with ocular complications on clinical grounds. investigated for microcephaly and suspected Split craniotomy was performed by a neurosurgeon to craniosynostosis. Radiographs of skull showed small relieve raised intracranial pressure and to enhance brain sized skull with early closure of sutures and fontanelle growth. Crouzon Syndrome was originally described in 1912 suggestive of craniosynstosis(Fig 2). A hammered- by Crouzon in a mother and her daughter. It is an autosomal silver (beaten metal/ copper beaten) appearance was dominant inherited disorder but represents fresh mutation also seen due to raised intracranial pressure and also. Crouzon syndrome is characterized by premature compression of the developing brain on the fused craniosynostosis which is quite variable but the coronal suture is nearly always bilaterally involved. Craniofacial bone. CT scan brain with contrast was done which abnormalities include brachycephaly, shallow orbits and confirmed the features suggestive of craniosynostosis maxillary hypoplasia. -
Genetics of Congenital Hand Anomalies
G. C. Schwabe1 S. Mundlos2 Genetics of Congenital Hand Anomalies Die Genetik angeborener Handfehlbildungen Original Article Abstract Zusammenfassung Congenital limb malformations exhibit a wide spectrum of phe- Angeborene Handfehlbildungen sind durch ein breites Spektrum notypic manifestations and may occur as an isolated malforma- an phänotypischen Manifestationen gekennzeichnet. Sie treten tion and as part of a syndrome. They are individually rare, but als isolierte Malformation oder als Teil verschiedener Syndrome due to their overall frequency and severity they are of clinical auf. Die einzelnen Formen kongenitaler Handfehlbildungen sind relevance. In recent years, increasing knowledge of the molecu- selten, besitzen aber aufgrund ihrer Häufigkeit insgesamt und lar basis of embryonic development has significantly enhanced der hohen Belastung für Betroffene erhebliche klinische Rele- our understanding of congenital limb malformations. In addi- vanz. Die fortschreitende Erkenntnis über die molekularen Me- tion, genetic studies have revealed the molecular basis of an in- chanismen der Embryonalentwicklung haben in den letzten Jah- creasing number of conditions with primary or secondary limb ren wesentlich dazu beigetragen, die genetischen Ursachen kon- involvement. The molecular findings have led to a regrouping of genitaler Malformationen besser zu verstehen. Der hohe Grad an malformations in genetic terms. However, the establishment of phänotypischer Variabilität kongenitaler Handfehlbildungen er- precise genotype-phenotype correlations for limb malforma- schwert jedoch eine Etablierung präziser Genotyp-Phänotyp- tions is difficult due to the high degree of phenotypic variability. Korrelationen. In diesem Übersichtsartikel präsentieren wir das We present an overview of congenital limb malformations based Spektrum kongenitaler Malformationen, basierend auf einer ent- 85 on an anatomic and genetic concept reflecting recent molecular wicklungsbiologischen, anatomischen und genetischen Klassifi- and developmental insights. -
Macrocephaly Information Sheet 6-13-19
Next Generation Sequencing Panel for Macrocephaly Clinical Features: Macrocephaly refers to an abnormally large head, OFC greater than 98th percentile, inclusive of the scalp, cranial bone and intracranial contents. Megalencephaly, brain weight/volume ratio greater than 98th percentile, results from true enlargement of the brain parenchyma [1]. Megalencephaly is typically accompanied by macrocephaly, however macrocephaly can occur in the absence of megalencephaly [2]. Both macrocephaly and megalencephaly can been seen as isolated clinical findings as well as clinical features of a mutli-systemic syndromic diagnosis. Our Macrocephaly Panel includes analysis of the 36 genes listed below. Macrocephaly Sequencing Panel ASXL2 GLI3 MTOR PPP2R5D TCF20 BRWD3 GPC3 NFIA PTEN TBC1D7 CHD4 HEPACAM NFIX RAB39B UPF3B CHD8 HERC1 NONO RIN2 ZBTB20 CUL4B KPTN NSD1 RNF125 DNMT3A MED12 OFD1 RNF135 EED MITF PIGA SEC23B EZH2 MLC1 PPP1CB SETD2 Gene Clinical Features Details ASXL2 Shashi-Pena Shashi et al. (2016) found that six patients with developmental delay, syndrome macrocephaly, and dysmorphic features were found to have de novo truncating variants in ASXL2 [3]. Distinguishing features were macrocephaly, absence of growth retardation, and variability in the degree of intellectual disabilities The phenotype also consisted of prominent eyes, arched eyebrows, hypertelorism, a glabellar nevus flammeus, neonatal feeding difficulties and hypotonia. BRWD3 X-linked intellectual Truncating mutations in the BRWD3 gene have been described in males with disability nonsyndromic intellectual disability and macrocephaly [4]. Other features include a prominent forehead and large cupped ears. CHD4 Sifrim-Hitz-Weiss Weiss et al., 2016, identified five individuals with de novo missense variants in the syndrome CHD4 gene with intellectual disabilities and distinctive facial dysmorphisms [5]. -
Sotos Syndrome
European Journal of Human Genetics (2007) 15, 264–271 & 2007 Nature Publishing Group All rights reserved 1018-4813/07 $30.00 www.nature.com/ejhg PRACTICAL GENETICS In association with Sotos syndrome Sotos syndrome is an autosomal dominant condition characterised by a distinctive facial appearance, learning disability and overgrowth resulting in tall stature and macrocephaly. In 2002, Sotos syndrome was shown to be caused by mutations and deletions of NSD1, which encodes a histone methyltransferase implicated in chromatin regulation. More recently, the NSD1 mutational spectrum has been defined, the phenotype of Sotos syndrome clarified and diagnostic and management guidelines developed. Introduction In brief Sotos syndrome was first described in 1964 by Juan Sotos Sotos syndrome is characterised by a distinctive facial and the major diagnostic criteria of a distinctive facial appearance, learning disability and childhood over- appearance, childhood overgrowth and learning disability growth. were established in 1994 by Cole and Hughes.1,2 In 2002, Sotos syndrome is associated with cardiac anomalies, cloning of the breakpoints of a de novo t(5;8)(q35;q24.1) renal anomalies, seizures and/or scoliosis in B25% of translocation in a child with Sotos syndrome led to the cases and a broad variety of additional features occur discovery that Sotos syndrome is caused by haploinsuffi- less frequently. ciency of the Nuclear receptor Set Domain containing NSD1 abnormalities, such as truncating mutations, protein 1 gene, NSD1.3 Subsequently, extensive analyses of missense mutations in functional domains, partial overgrowth cases have shown that intragenic NSD1 muta- gene deletions and 5q35 microdeletions encompass- tions and 5q35 microdeletions encompassing NSD1 cause ing NSD1, are identifiable in the majority (490%) of 490% of Sotos syndrome cases.4–10 In addition, NSD1 Sotos syndrome cases. -
KBG Syndrome Presenting with Brachydactyly Type E
Bone 123 (2019) 18–22 Contents lists available at ScienceDirect Bone journal homepage: www.elsevier.com/locate/bone Case Report KBG syndrome presenting with brachydactyly type E T ⁎ Renata Libiantoa,b,c, , Kathy HC Wud,e,f,g, Sophie Deveryd, John A Eismana,b,f,h, Jackie R Centera,b,f,h a Bone Division, Garvan Institute of Medical Research, Sydney, Australia b Department of Endocrinology, St Vincent's Hospital Sydney, Australia c Department of Medicine, The University of Melbourne, Australia d Clinical Genomics Unit, St Vincent's Hospital Sydney, Australia e Discipline of Genetic Medicine, University of Sydney, Australia f School of Medicine, UNSW, Sydney, Australia g Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, Australia h School of Medicine Sydney, University of Notre Dame, Australia ARTICLE INFO ABSTRACT Keywords: We report the case of a young woman who presented at age 10 years with height on the tenth centile, bra- KBG syndrome chydactyly type E and mild developmental delay. Biochemistry and hormonal profiles were normal. Differential ANKRD11 gene diagnoses considered included Albright hereditary osteodystrophy without hormone resistance (a.k.a pseu- Skeletal disorder dopseudohypoparathyroidism), 2q37 microdeletion syndrome and acrodysostosis. She had a normal karyotype Brachydactyly type E and normal FISH of 2q37. Whole genome sequencing (WGS) identified a mutation in the ANKRD11 gene as- sociated with KBG syndrome. We review the clinical features of the genetic syndromes considered, and suggest KBG syndrome be considered in patients presenting with syndromic brachydactyly type E, especially if short stature and developmental delay are also present. 1. Case support in a mainstream school for specific learning difficulties. -
Accelerating Matchmaking of Novel Dysmorphology Syndromes Through Clinical and Genomic Characterization of a Large Cohort
ORIGINAL RESEARCH ARTICLE © American College of Medical Genetics and Genomics Accelerating matchmaking of novel dysmorphology syndromes through clinical and genomic characterization of a large cohort Ranad Shaheen, PhD1, Nisha Patel, PhD1, Hanan Shamseldin, MSc1, Fatema Alzahrani, BSc1, Ruah Al-Yamany, MD1, Agaadir ALMoisheer, MSc1, Nour Ewida, BSc1, Shamsa Anazi, MSc1, Maha Alnemer, MD2, Mohamed Elsheikh, MD3, Khaled Alfaleh, MD3,4, Muneera Alshammari, MD4, Amal Alhashem, MD5, Abdullah A. Alangari, MD4, Mustafa A. Salih, MD4, Martin Kircher, MD6, Riza M. Daza, PhD6, Niema Ibrahim, BSc1, Salma M. Wakil, PhD1, Ahmed Alaqeel, MD7, Ikhlas Altowaijri, MD7, Jay Shendure, MD, PhD6, Amro Al-Habib, MD7, Eissa Faqieh, MD8 and Fowzan S. Alkuraya, MD1,9 Purpose: Dysmorphology syndromes are among the most common and C3ORF17). A significant minority of the phenotypes (6/31, 19%), referrals to clinical genetics specialists. Inability to match the dysmor- however, were caused by genes known to cause Mendelian pheno- phology pattern to a known syndrome can pose a major diagnostic chal- types, thus expanding the phenotypic spectrum of the diseases linked lenge. With an aim to accelerate the establishment of new syndromes to these genes. The conspicuous inheritance pattern and the highly and their genetic etiology, we describe our experience with multiplex specific phenotypes appear to have contributed to the high yield consanguineous families that appeared to represent novel autosomal (90%) of plausible molecular diagnoses in our study cohort. recessive dysmorphology syndromes at the time of evaluation. Conclusion: Reporting detailed clinical and genomic analysis of Methods: Combined autozygome/exome analysis of multiplex a large series of apparently novel dysmorphology syndromes will consanguineous families with apparently novel dysmorphology syn- likely lead to a trend to accelerate the establishment of novel syn- dromes. -
Lieshout Van Lieshout, M.J.S
EXPLORING ROBIN SEQUENCE Manouk van Lieshout Van Lieshout, M.J.S. ‘Exploring Robin Sequence’ Cover design: Iliana Boshoven-Gkini - www.agilecolor.com Thesis layout and printing by: Ridderprint BV - www.ridderprint.nl ISBN: 978-94-6299-693-9 Printing of this thesis has been financially supported by the Erasmus University Rotterdam. Copyright © M.J.S. van Lieshout, 2017, Rotterdam, the Netherlands All rights reserved. No parts of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without permission of the author or when appropriate, the corresponding journals Exploring Robin Sequence Verkenning van Robin Sequentie Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.A.P. Pols en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 20 september 2017 om 09.30 uur door Manouk Ji Sook van Lieshout geboren te Seoul, Korea PROMOTIECOMMISSIE Promotoren: Prof.dr. E.B. Wolvius Prof.dr. I.M.J. Mathijssen Overige leden: Prof.dr. J.de Lange Prof.dr. M. De Hoog Prof.dr. R.J. Baatenburg de Jong Copromotoren: Dr. K.F.M. Joosten Dr. M.J. Koudstaal TABLE OF CONTENTS INTRODUCTION Chapter I: General introduction 9 Chapter II: Robin Sequence, A European survey on current 37 practice patterns Chapter III: Non-surgical and surgical interventions for airway 55 obstruction in children with Robin Sequence AIRWAY OBSTRUCTION Chapter IV: Unravelling Robin Sequence: Considerations 79 of diagnosis and treatment Chapter V: Management and outcomes of obstructive sleep 95 apnea in children with Robin Sequence, a cross-sectional study Chapter VI: Respiratory distress following palatal closure 111 in children with Robin Sequence QUALITY OF LIFE Chapter VII: Quality of life in children with Robin Sequence 129 GENERAL DISCUSSION AND SUMMARY Chapter VIII: General discussion 149 Chapter IX: Summary / Nederlandse samenvatting 169 APPENDICES About the author 181 List of publications 183 Ph.D. -
(12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008. -
Identifying the Misshapen Head: Craniosynostosis and Related Disorders Mark S
CLINICAL REPORT Guidance for the Clinician in Rendering Pediatric Care Identifying the Misshapen Head: Craniosynostosis and Related Disorders Mark S. Dias, MD, FAAP, FAANS,a Thomas Samson, MD, FAAP,b Elias B. Rizk, MD, FAAP, FAANS,a Lance S. Governale, MD, FAAP, FAANS,c Joan T. Richtsmeier, PhD,d SECTION ON NEUROLOGIC SURGERY, SECTION ON PLASTIC AND RECONSTRUCTIVE SURGERY Pediatric care providers, pediatricians, pediatric subspecialty physicians, and abstract other health care providers should be able to recognize children with abnormal head shapes that occur as a result of both synostotic and aSection of Pediatric Neurosurgery, Department of Neurosurgery and deformational processes. The purpose of this clinical report is to review the bDivision of Plastic Surgery, Department of Surgery, College of characteristic head shape changes, as well as secondary craniofacial Medicine and dDepartment of Anthropology, College of the Liberal Arts characteristics, that occur in the setting of the various primary and Huck Institutes of the Life Sciences, Pennsylvania State University, State College, Pennsylvania; and cLillian S. Wells Department of craniosynostoses and deformations. As an introduction, the physiology and Neurosurgery, College of Medicine, University of Florida, Gainesville, genetics of skull growth as well as the pathophysiology underlying Florida craniosynostosis are reviewed. This is followed by a description of each type of Clinical reports from the American Academy of Pediatrics benefit from primary craniosynostosis (metopic, unicoronal, bicoronal, sagittal, lambdoid, expertise and resources of liaisons and internal (AAP) and external reviewers. However, clinical reports from the American Academy of and frontosphenoidal) and their resultant head shape changes, with an Pediatrics may not reflect the views of the liaisons or the emphasis on differentiating conditions that require surgical correction from organizations or government agencies that they represent. -
Diagnosis of Lethal Or Prenatal-Onset Autosomal Recessive Disorders by Parental Exome Sequencing
DOI: 10.1002/pd.5175 SPECIAL TOPIC ISSUE ON ADVANCES IN THE DIAGNOSIS OF SINGLE GENE DISORDERS Diagnosis of lethal or prenatal-onset autosomal recessive disorders by parental exome sequencing Karen L. Stals1 , Matthew Wakeling2, Júlia Baptista1,2, Richard Caswell2, Andrew Parrish1, Julia Rankin3, Carolyn Tysoe1, Garan Jones1, Adam C. Gunning1, Hana Lango Allen2, Lisa Bradley4, Angela F. Brady5, Helena Carley6, Jenny Carmichael7, Bruce Castle3, Deirdre Cilliers8, Helen Cox9, Charu Deshpande6, Abhijit Dixit10, Jacqueline Eason10, Frances Elmslie11, Andrew E. Fry12, Alan Fryer13, Muriel Holder6, Tessa Homfray11, Emma Kivuva3, Victoria McKay13, Ruth Newbury-Ecob14, Michael Parker15, Ravi Savarirayan16, Claire Searle10, Nora Shannon10, Deborah Shears8, Sarah Smithson14, Ellen Thomas6, Peter D. Turnpenny3, Vinod Varghese12, Pradeep Vasudevan17, Emma Wakeling6, Emma L. Baple2,3,18 and Sian Ellard1,2* 1Molecular Genetics Department, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK 2Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK 3Clinical Genetics Department, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK 4Department of Clinical Genetics, Our Lady’s Children’s Hospital, Dublin, Ireland 5North West Thames Regional Genetics Service, London North West Healthcare NHS Trust, Harrow, UK 6Guy’s Regional Genetics Service, Guy’s and St Thomas’ NHS Foundation Trust, London, UK 7Oxford Regional Clinical Genetics Service, Northampton General Hospital, Northampton, UK 8Oxford Centre for Genomic